IL302244A - Antibodies against SARS-COV-2 and their uses - Google Patents

Antibodies against SARS-COV-2 and their uses

Info

Publication number
IL302244A
IL302244A IL302244A IL30224423A IL302244A IL 302244 A IL302244 A IL 302244A IL 302244 A IL302244 A IL 302244A IL 30224423 A IL30224423 A IL 30224423A IL 302244 A IL302244 A IL 302244A
Authority
IL
Israel
Prior art keywords
yang
antibody
impi
domain
domain sequence
Prior art date
Application number
IL302244A
Other languages
English (en)
Hebrew (he)
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of IL302244A publication Critical patent/IL302244A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
IL302244A 2020-10-27 2021-10-27 Antibodies against SARS-COV-2 and their uses IL302244A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Publications (1)

Publication Number Publication Date
IL302244A true IL302244A (en) 2023-06-01

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302244A IL302244A (en) 2020-10-27 2021-10-27 Antibodies against SARS-COV-2 and their uses

Country Status (12)

Country Link
US (1) US20250026813A1 (enExample)
EP (1) EP4237442A1 (enExample)
JP (1) JP2023549067A (enExample)
KR (1) KR20230113295A (enExample)
CN (1) CN117396501A (enExample)
AU (1) AU2021369450A1 (enExample)
CA (1) CA3199594A1 (enExample)
CO (1) CO2023006684A2 (enExample)
GB (1) GB202017058D0 (enExample)
IL (1) IL302244A (enExample)
MX (1) MX2023004869A (enExample)
WO (1) WO2022090353A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN121002058A (zh) * 2022-12-09 2025-11-21 艾布维兹生物公司 针对SARS-CoV-2及其变体的抗体或其片段
CN120981481A (zh) * 2023-01-10 2025-11-18 萨那生物技术股份有限公司 Cd19特异性抗体构建体以及它们的组合物
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof

Also Published As

Publication number Publication date
AU2021369450A9 (en) 2025-04-10
CN117396501A (zh) 2024-01-12
WO2022090353A1 (en) 2022-05-05
US20250026813A1 (en) 2025-01-23
EP4237442A1 (en) 2023-09-06
AU2021369450A1 (en) 2023-06-22
GB202017058D0 (en) 2020-12-09
JP2023549067A (ja) 2023-11-22
MX2023004869A (es) 2023-06-01
CO2023006684A2 (es) 2023-05-29
KR20230113295A (ko) 2023-07-28
CA3199594A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
US20250026813A1 (en) Antibodies against sars-cov-2 and uses thereof
US12435134B2 (en) Antagonists anti-CD7 antibodies
JP2024075741A (ja) イヌ化抗体
CN103080132B (zh) 抗il-18r1的抗体及其用途
TWI613214B (zh) 抗血球凝集素抗體及使用方法
KR20150131177A (ko) 항-CRTh2 항체 및 그의 용도
EP3218397B1 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
CN118829653A (zh) 用tl1a抑制剂和il23抑制剂的组合治疗炎性疾病的方法
CN115210258A (zh) 特异性识别胸腺基质淋巴细胞生成素的抗体及其用途
US20220380441A1 (en) Antibody compositions and methods for treating hepatitis b virus infection
US20240270828A1 (en) Human neutralizing antibodies against sars-cov-2 spike s2 domain and uses thereof
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
US20240092872A1 (en) Compositions and methods for treating hepatitis b virus infection
EP4565329A1 (en) Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
JP2024533166A (ja) 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
EP4208479A1 (en) Human monoclonal antibodies to sars-cov-2 and use thereof
WO2025184137A1 (en) Influenza antibodies and methods of use thereof
WO2024120516A1 (zh) 特异性结合rsv的抗体
WO2022162097A2 (en) Antibodies and uses thereof
WO2023201256A1 (en) High dose antibody therapies for sars-cov-2 infection
WO2023034871A1 (en) High concentration antibody therapies for sars-cov-2 infection
CN116916958A (zh) 用于sars-cov-2感染的抗体疗法
CN119213024A (zh) hMPV抗体及其用途
TW202309075A (zh) 對冠狀病毒s蛋白質具特異性之化合物及其用途
HK40057872A (en) Neutralizing antibodies to ebola virus glycoprotein and their use